{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:20:18Z","timestamp":1786990818401,"version":"build-2736575974"},"reference-count":29,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100017183","name":"Janssen Scientific Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017183","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.ijrobp.2020.11.059","type":"journal-article","created":{"date-parts":[[2020,11,28]],"date-time":"2020-11-28T11:12:46Z","timestamp":1606561966000},"page":"1271-1278","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Combination of Radiation Therapy and\u00a0Short-Term Androgen Blockade With Abiraterone Acetate Plus Prednisone for Men\u00a0With High- and Intermediate-Risk Localized Prostate Cancer"],"prefix":"10.1016","volume":"109","author":[{"given":"Bridget F.","family":"Koontz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen E.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Halabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Healy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Anand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Corn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Robert","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Armstrong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2020.11.059_bib1","doi-asserted-by":"crossref","first-page":"126","DOI":"10.2105\/AJPH.91.1.126","article-title":"Patterns of prostate cancer treatment by clinical stage and age","volume":"91","author":"Meltzer","year":"2001","journal-title":"Am J Public Health"},{"key":"10.1016\/j.ijrobp.2020.11.059_bib2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1532-5415.2005.00567.x","article-title":"Quality of life in prostate cancer patients taking androgen deprivation therapy","volume":"54","author":"Dacal","year":"2006","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.ijrobp.2020.11.059_bib3","doi-asserted-by":"crossref","first-page":"3571","DOI":"10.1158\/1078-0432.CCR-12-0908","article-title":"Abiraterone inhibits 3beta-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer","volume":"18","author":"Li","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2020.11.059_bib4","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"de Bono","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2020.11.059_bib5","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(12)61253-7","article-title":"Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)","volume":"380","author":"Bolla","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2020.11.059_bib6","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2020.11.059_bib7","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1158\/2159-8290.CD-13-0172","article-title":"Androgen receptor signaling regulates DNA repair in prostate cancers","volume":"3","author":"Polkinghorn","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ijrobp.2020.11.059_bib8","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1158\/2159-8290.CD-13-0108","article-title":"A hormone-DNA repair circuit governs the response to genotoxic insult","volume":"3","author":"Goodwin","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ijrobp.2020.11.059_bib9","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.urology.2010.01.027","article-title":"Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors","volume":"76","author":"Szymanski","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.ijrobp.2020.11.059_bib10","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1002\/cncr.21077","article-title":"Undetectable prostate specific antigen at 6-12 months: A new marker for early success in hormonally treated patients after prostate brachytherapy","volume":"103","author":"Miller","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2020.11.059_bib11","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.urology.2018.11.056","article-title":"Time to prostate-specific antigen nadir and the risk of death from prostate cancer following radiation and androgen deprivation therapy","volume":"126","author":"Pike","year":"2019","journal-title":"Urology"},{"key":"10.1016\/j.ijrobp.2020.11.059_bib12","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1002\/cncr.28019","article-title":"Prostate-specific antigen response after short-term hormone therapy plus external-beam radiotherapy and outcome in patients treated on Radiation Therapy Oncology Group study 9413","volume":"119","author":"Cury","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2020.11.059_bib13","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.urology.2014.08.044","article-title":"Minimally important difference for the Expanded Prostate Cancer Index Composite Short Form","volume":"85","author":"Skolarus","year":"2015","journal-title":"Urology"},{"key":"10.1016\/j.ijrobp.2020.11.059_bib14","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1002\/cncr.32778","article-title":"Validation of a subclassification for high-risk prostate cancer in a prospective cohort","volume":"126","author":"Butler","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2020.11.059_bib15","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1012348","article-title":"Radiotherapy and short-term androgen deprivation for localized prostate cancer","volume":"365","author":"Jones","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2020.11.059_bib16","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1056\/NEJMoa0810095","article-title":"Duration of androgen suppression in the treatment of prostate cancer","volume":"360","author":"Bolla","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2020.11.059_bib17","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S1470-2045(10)70223-0","article-title":"External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study","volume":"11","author":"Bolla","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2020.11.059_bib18","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.eururo.2008.10.008","article-title":"Androgen deprivation therapy for the treatment of prostate cancer: Consider both benefits and risks","volume":"55","author":"Isbarn","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2020.11.059_bib19","doi-asserted-by":"crossref","first-page":"5038","DOI":"10.1200\/JCO.2010.29.8091","article-title":"Impact of androgen-deprivation therapy on physical function and quality of life in men with nonmetastatic prostate cancer","volume":"28","author":"Alibhai","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2020.11.059_bib20","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1200\/JCO.2013.53.4578","article-title":"Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: Results of a randomized phase II neoadjuvant study","volume":"32","author":"Taplin","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2020.11.059_bib21","doi-asserted-by":"crossref","first-page":"18","DOI":"10.4111\/icu.2018.59.1.18","article-title":"Factors associated with testosterone recovery after androgen deprivation therapy in patients with prostate cancer","volume":"59","author":"Nam","year":"2018","journal-title":"Investig Clin Urol"},{"key":"10.1016\/j.ijrobp.2020.11.059_bib22","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/S0022-5347(05)66910-8","article-title":"A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy","volume":"164","author":"Nejat","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.ijrobp.2020.11.059_bib23","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.ijrobp.2018.11.007","article-title":"A nomogram for testosterone recovery after combined androgen deprivation and radiation therapy for prostate cancer","volume":"103","author":"Spiegel","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.11.059_bib24","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.ijrobp.2020.06.017","article-title":"Impact of sequencing of androgen suppression and radiation therapy on testosterone recovery in localized prostate cancer","volume":"108","author":"Roy","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.11.059_bib25","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.eururo.2018.02.012","article-title":"Effect of prostate cancer severity on functional outcomes after localized treatment: Comparative effectiveness analysis of surgery and radiation study results","volume":"74","author":"Tyson","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2020.11.059_bib26","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1002\/cncr.31400","article-title":"Three-month posttreatment prostate-specific antigen level as a biomarker of treatment response in patients with intermediate-risk or high-risk prostate cancer treated with androgen deprivation therapy and radiotherapy","volume":"124","author":"Bryant","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2020.11.059_bib27","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaoncol.2016.5983","article-title":"Surrogate end points for all-cause mortality in men with localized unfavorable-risk prostate cancer treated with radiation therapy vs radiation therapy plus androgen deprivation therapy: A secondary analysis of a randomized clinical trial","volume":"3","author":"Royce","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2020.11.059_bib28","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ijrobp.2011.11.047","article-title":"Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer","volume":"84","author":"Zelefsky","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2020.11.059_bib29","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.2015.64.8055","article-title":"Short androgen suppression and radiation dose escalation for intermediate- and high-risk localized prostate cancer: Results of EORTC Trial 22991","volume":"34","author":"Bolla","year":"2016","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301620345995?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301620345995?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T09:54:54Z","timestamp":1759744494000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301620345995"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S0360301620345995"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2020.11.059","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combination of Radiation Therapy and\u00a0Short-Term Androgen Blockade With Abiraterone Acetate Plus Prednisone for Men\u00a0With High- and Intermediate-Risk Localized Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2020.11.059","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}